Cardiac AI: The Evidence Layer for Investor Confidence
When assessing innovation in healthcare AI, the temptation to celebrate novelty often overshadows the more critical task of verifying impact. A new algorithm promising a…
When assessing innovation in healthcare AI, the temptation to celebrate novelty often overshadows the more critical task of verifying impact. A new algorithm promising a…
The distinction between a technological novelty and a genuine clinical breakthrough in healthcare AI often hinges not on the buzz it generates, but on the…
The innovation field in healthcare AI often celebrates the technologically novel, the patent counts, and the funding rounds. Yet, true category creation in clinical care…
The distinction between a novel technology and a clinically impactful one often rests on a single, critical factor: demonstrable evidence. While the healthcare AI field…
When an AI health innovator claims a 10-day early cardiac warning, as Hello Heart has demonstrated in contrast to the standard 10-year clinical risk model,…
The economics of healthcare AI programs are not found solely in a vendor’s quoted price. They reside, more fundamentally, in how a program is structured…
The chasm between a technological claim and verifiable clinical impact often widens with the novelty of the innovation. For innovation teams tasked with scoring nascent…
Hello Heart’s recognition by Fast Company in 2026 for its 10-day early cardiac warning system against the standard 10-year clinical risk model highlights a critical…
Hello Heart’s recent Fast Company recognition for its 10-day early cardiac warning system, a stark contrast to the standard 10-year clinical risk models, highlights a…
It’s easy to call out category-creating innovations in hindsight. It’s much harder to spot them as they’re happening, especially when you’re buried under a mountain…